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The recognition and precise cleavage of the polypurine tract (PPT) of the human immunodeficiency virus type 1 (HIV-1) is an essential step in
HIV-1 reverse transcription. The accurate cleavage, and the subsequent removal, of the PPT by the RNase H activity of HIV-1 RT defines the left
end of the double-stranded viral DNA genome, the substrate for integration into the host genome. Previous analyses have shown that mutations in
the 3′-end (G-tract) of the PPT cause alterations in RNase H cleavage specificity. In particular, mutations at positions 2 and 5 in the G-tract
increased the frequency of retention of PPT sequences in the 2-LTR circle junction. To better understand why these mutations affected PPT
cleavage in vivo, we analyzed the cleavage of PPT substrates in vitro that contained altered sequences and unusual base substitutions. Our results,
herein, confirm that mutations at positions 2 and 5 of the G-tract do significantly alter the cleavage specificity at the PPT/U3 junction, and further
suggest that the miscleavages observed in vivo were due to an improper generation of the PPT primer, as opposed to its improper removal. Finally,
our results point to the structure of the PPT, rather than the base-specific contacts between the PPT and HIV-1 RT, as the primary determinants of
RNase H cleavage specificity at the PPT/U3 junction.
© 2006 Elsevier Inc. All rights reserved.Keywords: HIV-1; Polypurine tract; PPT; Ribonuclease H; RNase H; G-tract; G-boxIntroduction
Human immunodeficiency virus type 1 (HIV-1) reverse
transcriptase (RT) is a virally encoded enzyme that catalyzes the
synthesis of double-stranded (ds) DNA from the single-stranded
(ss) viral RNA genome, a reaction that is essential for viral
DNA synthesis, and by extension, for HIV-1 replication
(Telesnitsky and Goff, 1997; Whitcomb and Hughes, 1992).
The successful conversion of viral RNA into dsDNA involves
the two enzymatic activities of RT, a DNA polymerase that can
copy either an RNA or a DNA template, and a ribonuclease H
(RNase H) that degrades RNAwhen it is part of an RNA/DNA
duplex. Both of these activities are essential, in that mutations
which inactivate either the polymerase or the RNase H block⁎ Corresponding author. Fax: +1 301 846 6966.
E-mail address: hughes@ncifcrf.gov (S.H. Hughes).
0042-6822/$ - see front matter © 2006 Elsevier Inc. All rights reserved.
doi:10.1016/j.virol.2006.10.008viral replication (Repaske et al., 1989; Telesnitsky et al., 1992;
Tisdale et al., 1991).
HIV-1 RT is a heterodimer consisting of 66 kDa and 51 kDa
subunits (Di Marzo Veronese et al., 1986). The DNA poly-
merase and RNase H active sites are within the p66 subunit of
the heterodimer; the p51 subunit is thought to play largely a
structural role (Le Grice et al., 1991). HIV-1 reverse transcrip-
tion is initiated from the 3′-end of a host-derived tRNA primer
that base pairs with the primer binding site (PBS) near the 5′-
end of the viral RNA genome (Fig. 1) (Telesnitsky and Goff,
1997; Whitcomb and Hughes, 1992). The RNA strand is plus
strand; the first DNA strand to be synthesized is the minus
strand. Initiation of minus strand DNA synthesis generates an
RNA/DNA duplex that is a substrate for RNase H. The ends of
the viral RNA genome are redundant, and degradation of the
viral RNA after it has been copied into DNA allows for transfer
of the minus strand DNA to the 3′-end of the viral RNA, where
DNA synthesis (and RNase H cleavage) continues.
Fig. 1. Reverse transcription of viral RNA. (A) Retroviral minus-strand DNA
synthesis is initiated from the 3′-end of a host-derived tRNA primer that base
pairs with the primer binding site (PBS) near the 5′-end of the viral RNA
genome. DNA synthesis generates an RNA/DNA duplex that is a substrate for
RNase H. (B) Degradation of the viral RNA in the RNA/DNA duplex allows
transfer of the minus-strand DNA to the 3′-end of the RNA allowing DNA
synthesis to continue. (C) The PPT is relatively resistant to RNase H
degradation, allowing it to serve as the primer for plus-strand DNA synthesis.
(D) The plus-strand primer is then transferred to complementary sequences at
the 3′-end of the template and plus-strand DNA synthesis is completed.
Removal of the tRNA and PPT primer defines the right and left ends of the viral
DNA genome, respectively.
Fig. 2. Model of the RNA/DNA nucleic acid substrate used in the RNase H
assay to monitor cleavage specificity at the PPT/U3 junction. The PPT region is
highlighted and the respective positions of the U-tract/PPTand PPT/U3 cleavage
sites are indicated. DNA and RNA strands are indicated in uppercase and
lowercase letters, respectively. The location of the G-tract is underlined.
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conserved sequence element found within the RNA genomes of
all retroviruses, and unlike most viral RNA sequences which are
susceptible to RNase H cleavage, the PPT is relatively resistant.
While most RNase H-mediated cleavage events appear to be
relatively nonspecific, the ends of the PPT sequence (the PPT/
U3 junction and U-tract/PPT junction, respectively) are
accurately cleaved by RNase H, generating a specific primer
that is used for the initiation of plus-strand DNA synthesis (see
Fig. 2). After plus-strand DNA synthesis has been initiated, the
PPT/U3 junction is again cleaved by RNase H to remove the
PPT primer and define the left (U3) end of the double-stranded
DNAviral genome, the substrate for subsequent integration into
the host genome. In addition to the PPT primer, RNase H also
specifically removes the tRNA primer used to initiate minus-
strand DNA synthesis. In HIV-1, this cleavage occurs one
nucleotide from the RNA/DNA junction and defines the right
(U5) end of the linear viral DNA (Furfine and Reardon,
1991a,1991b; Pullen et al., 1992; Smith and Roth, 1992;
Whitcomb and Hughes, 1992).
While it is clear that HIV-1 RTcleaves its genome to generate
the PPT primer in a highly efficient and specific manner, the
mechanism(s) that determine the specificity of these cleavage
events remain ill-defined. Several lines of evidence suggest that
it is the structure of the PPT in a complex with HIV-1 RT that
determines RNase H cleavage specificity. Recent crystal-
lographic and NMR analyses of PPT-containing RNA/DNA
and DNA/DNA duplexes have revealed that the A-tracts in the
PPT have a narrow minor groove and unusual C2-endo sugar
conformation (Han et al., 1997; Horton and Finzel, 1996;
Kopka et al., 2003; Lankas et al., 2002). Furthermore, thereappear to be two unpaired and two mispaired bases that take the
normal base pairing of the PPT out of, and then back into,
register within the RNA/DNA template/primer when it is in a
complex with HIV-1 RT. There is a network of amino acids that
contact the primer strand near the RNase H active site, known as
the RNase H primer grip, that has been proposed to play a
critical role in the interactions between the RNase H domain of
HIV-1 RTand its nucleic acid substrate (Sarafianos et al., 2001).
Although the unusual structural features of the PPT would
appear to suggest structure has a role in determining RNase H
cleavage specificity, the available data from studies on the
effects of PPT mutations on RNase H cleavage activity are
inconsistent (Dash et al., 2004; Kvaratskhelia et al., 2002;
Powell and Levin, 1996; Rattray and Champoux, 1989; Rausch
et al., 2003). Moreover, most of these experiments were
conducted in vitro and there is no corresponding in vivo data for
most of the mutants that were analyzed. Some groups have
reported that sequence alterations in either the 5′- or 3′-end of
the PPT affect cleavage specificity (Kvaratskhelia et al., 2002).
Others suggested that the 3′-end, and not the 5′-end, contains
the critical determinants (Powell and Levin, 1996; Pullen et al.,
1993). Because these assays involved different nucleotide
substitutions, it was difficult to compare and contrast the data.
We have analyzed mutants with alterations in the RNase H
domain of RT and these experiments have shown good overall
agreement between both in vivo and in vitro systems (Julias et
al., 2002; Rausch et al., 2002), particularly with respect to
which mutations had the greatest effect on cleavage specificity.
That said, the in vitro data did not, in all cases, fully explain the
specific miscleavages observed in vivo (Julias et al., 2002).
2-LTR circular viral DNAs, found in the nuclei of infected
cells, are formed by the host-mediated ligation of the LTR ends
of the viral genome (Li et al., 2001). Sequence analysis of the
LTR junctions in these 2-LTR circles is a convenient way to
monitor RNase H cleavage specificity in vivo, because the ends
of the linear viral DNA that are defined by specific RNase H
cleavages are preserved in the subsequent ligation reaction that
generates the 2-LTR circle junction. As such, mutations that
affect the specificity of RNase H in the generation and/or
removal of the PPT primer will alter the proportion of linear
viral DNA that contains aberrant ends. By performing 2-LTR
circle junction analyses, we previously showed that mutations
in both the 5′- and 3′-ends of the PPT affect RNase H cleavage
specificity in vivo (Julias et al., 2004). We showed that most
single point mutations in the G-tract at the 3-end of the PPT had
modest effects on viral titer and RNase H cleavage specificity,
Fig. 3. Cleavage of mutant PPTs by wild-type HIV-1 RT. (A) Comparison of the
RNase H cleavage profile for wild-type, U2, A5, A2/A5 and C2/C5 mutant PPTs
by wild-type HIV-1 RT. The RNA template was 5′-end labeled, annealed to its
complementary DNA strand, and cleaved with HIV-1 RT for 5 min at 37 °C.
Cleavage products were resolved on a 12% denaturing gel. The full-length 5′-
end-labeled RNA and site of PPT/U3 cleavage is indicated to the right of the gel.
(B) Summary of the cleavage specificity for the wild-type and mutant PPT
substrates. Major and minor cleavage sites are indicated with large and small
arrows, respectively.
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effect on cleavage specificity and lead to an increased fraction
of 2-LTR circle junctions with inserted sequences. Although the
3′-end of the PPT was shown to be important for RNase H
cleavage specificity in the in vivo experiments, the data did not
adequately explain how PPT mutations affected the PPT
processing. We wanted to answer two questions: first, was the
increased fraction of 2-LTR circles that contained insertions of
PPT sequences at their LTR junction due to a failure to properly
generate, or remove, the PPT primer? Second, how do particular
mutations in the PPTor the RT cause the RNase H to miscleave?
In order to better understand the effects that mutations in the
G-tract of the HIV-1 PPT had on RNase H cleavage in vivo, and
to further dissect the mechanism(s) of the PPT cleavages in
general, we proceeded to perform a detailed set of in vitro
analyses. Unlike the in vivo system for characterizing RNase H
cleavage, which is limited to the analysis of final products of
reverse transcription, RNase H cleavage assays performed in
vitro allow for a direct assessment of PPT specificity and
cleavage efficiency. Another advantage of the in vitro system is
that both conventional base substitutions and modified bases
can be used to dissect the importance of putative contacts
between RT and the PPT template. In complementing and
extending the knowledge gained from our previous in vivo
experiments and in vitro experiments (Rausch et al., 2002;
Julias et al., 2004; McWilliams et al., 2006), the current data
provide insight(s) into the mechanism of specific recognition
and cleavage of the PPT by the RNase H activity of HIV-1 RT.
Our results suggest that the structure of the PPT, as opposed to
the base-specific contacts between the PPT and HIV-1 RT, is the
primary determinant of RNase H cleavage specificity at the
PPT/U3 junction and that previously observed miscleavages in
vivo were due to an improper generation of the PPT primer.
Results
Miscleavages at the PPT/U3 junction gives rise to aberrant
viral DNA ends
The PPT of HIV-1 has a G-tract (Fig. 2), a sequence of six
contiguous G's at the 3′-end, which is highly conserved in
human and simian lentiviruses, and is moderately conserved
among other retroviruses (Julias et al., 2004). Using the
sequence of the 2-LTR circle junction as a surrogate for the
ends of the viral DNA, we previously showed that specific
mutations in the G-tract of the PPT can cause significant
alterations in the in vivo specificity of RNase H cleavage by
HIV-1 RT (Julias et al., 2004). To better understand these
observations, and determine whether the RNase H cleavages
involved in generating or removing the PPT primer are
responsible for creating aberrant ends in the linear viral DNA,
we used an in vitro RNase H PPTcleavage assay. In brief, RNA/
DNA substrates were prepared that contained the entire HIV-1
PPT sequence, portions of the U3 sequences that are adjacent to
the PPT, and the 5′ U-tract sequence, previously shown to be
important for viral replication (Bacharach et al., 2000; Ilyinskii
and Desrosiers, 1998; Robson and Telesnitsky, 1999) (Fig. 2).5′-End labeled RNA primers were annealed to their comple-
mentary DNA templates, incubated in the presence of HIV-1
RT, and the cleavage products were fractioned by denaturing
polyacrylamide gel electrophoresis. As expected, based on
previous in vitro HIV-1 RNase H cleavage assays (Kvaratskhe-
lia et al., 2002), wild-type HIV-1 RT generated two cleavage
products from the wild-type RNA/DNA PPT substrate (Fig. 3A,
lane 1): a 22 nt major product, indicating precise cleavage at the
PPT/U3 junction, and a 15 nt minor product, indicating
cleavage 7 nt upstream of the PPT/U3 junction.
Consistent with our previous assessment of in vivo results
(Julias et al., 2004), most single nucleotide substitutions in the
G-tract (Fig. 3B) had a moderate effect on the processing of the
PPT/U3 junction in vitro. Single nucleotide substitution
mutations at positions 2 and 5, U2 and A5 respectively, resulted
in the generation of the major cleavage product (22 nt) and
several minor cleavage products (<15 nt) when cleaved by
wild-type HIV-1 RT (U2 and A5, Fig. 3A). The single
nucleotide substitution that had the greatest effect was U5,
which caused a strong attenuation of PPT/U3 junction cleavage
in vitro (U5, Fig. 4A). The equivalent T5 single nucleotide
Fig. 4. Cleavage of mutant PPTs by wild-type HIV-1 RT. (A) Comparison of the
RNase H cleavage profile wild-type, I5, U5, and U2/U5 mutant PPTs by wild-
type HIV-1 RT. Reactions were performed as described in Fig. 3. The full-length
5′-end-labeled RNA and the site of PPT/U3 cleavage are indicated by arrows to
the left of the gel. (B) Summary of the cleavage specificity of wild-type and
mutant PPT substrates (I5, U5, U2/U5). Major and minor cleavage sites are
indicated with large and small arrows, respectively.
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consensus 2-LTR circle junctions in vivo (Julias et al., 2004).
Double substitutions at both G-tract positions 2 and 5
caused a much greater reduction of PPT/U3 cleavage
specificity measured by the generation of aberrant 2-LTR circle
junctions (Julias et al., 2004). The U2/U5 double substitution
had the greatest effect; this mutant was called T2–5 in the in
vivo assays. We found that T2–5 caused a 10-fold reduction in
virus titer and an increase in the percentage of 2-LTR circle
junctions containing a one-nucleotide (G) insertion at the end of
U3. In the in vitro assay, the corresponding substrate was not
cleaved at the true PPT/U3 junction (Fig. 4A, lane 4), even after
extended periods of time (data not shown). For this mutant, the
primary site of cleavage was in the (modified) PPT one
nucleotide 5′ of the PPT/U3 junction, which would explain the
insertion of the G found at the 2-LTR circle junction in vivo
(Fig. 4). There were two additional minor cleavages, one two
nucleotides 5′, and the other two nucleotides 3′ of the true PPT/
U3 junction. While the A2/A5 mutant was also found to cause a
decreased proportion of consensus 2-LTR circle junctions, the
primary difference was that the A2/A5 mutation caused the
accumulation of 2-LTR circle junctions with a two nucleotide
(AG) insertion at the end of U3. The in vitro RNase H cleavage
assays showed that this G-tract double mutant caused an
alternative cleavage in the (modified) PPT two nucleotides 5′ of
the PPT/U3 junction (see Fig. 3) that would explain the
insertion of two nucleotides at the 2-LTR circle junction (Fig.
3A, lane 4). Finally, the C2/C5 double mutant was also found tocause altered cleavage of the PPT (Fig. 3A, lane 5). In this case,
cleavage of the true PPT/U3 junction was not eliminated, but
there was a significant increase in the amount of miscleavages
in the PPT one and two nucleotides 5′ of the PPT/U3 junction.
Because the miscleavage event(s) seen for these G-tract
mutants would generate the nucleotide insertions previously
seen at 2-LTR circle junctions, these results suggest that the G
and AG insertions at the 2-LTR circle junction were the result
of a failure to generate the appropriate PPT primer as opposed
to a failure to completely remove a properly generated PPT
primer (see Fig. 8).
Base specific contacts do not play a critical role in determining
cleavage specificity at the PPT/U3 junction
Although most RT contacts with the PPT template involve
the sugar-phosphate backbone, base-specific contacts do exist.
In the crystal structure of HIV-1 RT, bound to an RNA/DNA
duplex whose sequence contains the PPT, amino acid residues
of the RNase H primer grip make interactions with the PPT that
may be important for RNase H catalysis and cleavage
specificity (Sarafianos et al., 2001). Molecular modeling
based on this structure suggested that the carboxyl group of
one of these residues, Q475, would make a base-specific contact
with the 2′-amino group of G5 near the PPT/U3 cleavage site.
Because this contact may serve to position the nucleic acid
substrate appropriately so that there can be precise RNase H
cleavage at the PPT/U3 junction, we investigated its importance
by substituting inosine at position 5 (I5). Inosine is a guanosine
analog that lacks an N2 exocyclic amine (see Fig. 5), which
should abrogate the Q475 2′-amino contact. As shown in Fig.
4A, the I5 substitution significantly disrupted RNase H
cleavage specificity at the PPT/U3 junction, suggesting that
the Q475 contact with the 2′-amino group of position G2 is
important for efficient cleavage at the PPT/U3 junction. An
inosine substitution was also introduced at position G2 (mutant
I2). There is no potential for a base-specific contact with the 2′-
amino group at position 2 and this inosine substitution did not
substantially affect cleavage at the PPT/U3 junction (I2, Fig. 6,
lane 7).
In light of the fact that inosine substitutions within the PPT
could affect duplex stability, we repeated the RNase H cleavage
assay using the Q475A RT mutant as a way to investigate the
importance of the putative interaction between Q475 and G5.
The Q475A mutant cleaved the wild-type PPT/U3 junction with
good specificity, arguing that the contact with the amino group
on G5 is not essential for PPT cleavage specificity (Fig. 7, lane
11). If the primary role of the Q475 carboxyl group is to make a
direct hydrogen bond to the 2′-amino group of G5, eliminating
both functional groups would not cause any further loss in
specificity of cleavage at the PPT/U3 junction. Both the Q475A
mutant and WT HIV-1 RT cleaved the wild-type substrate and
I5 PPT mutant similarly (Fig. 7, lanes 4 and 14). That is, both
cleaved the wild-type substrate with considerable precision;
neither cleaved the I5 PPT/U3 junction accurately. The data
obtained with the Q475A mutant argue that it is the structural
contribution of the 2-amino group at position G5, as opposed to
Fig. 6. Substitution of inosine or 2-aminopurine at position G5 (I5 and 2AP
mutants), but not position G2 (I2 mutant) alters PPTcleavage specificity in vitro.
Cleavage assays were performed as described (see Materials and methods). The
full-length 5′-end-labeled RNA and the site of PPT/U3 cleavage is indicated by
arrows to the right of the gels.
Fig. 5. Chemical structure of the guanosine analogs used in the RNase H PPT
cleavage assay. Inosine lacks the N2 exocylic amine of guanosine; 2-
aminopurine lacks the C6 carboxyl group.
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mediating RNase H cleavage specificity at the PPT/U3 junction.
This proposal is supported by analysis of the miscleavages
made by viral vectors that had mutations at both positions 475
of RTand in G5 of the PPT (McWilliams et al., 2006). However,
the in vitro results obtained comparing the cleavages of the
wild-type and I5 substrates by wild-type and the Q475A mutant
suggested additional experiments were warranted.
In defining the role of the G5 residue, we wondered whether
the C6 carboxyl group of G5, as opposed to the G5 amino
group, was important. For these experiments, we used the
analog 2-aminopurine (2AP), which differs from guanine only
in that it lacks the C6 carboxyl group; importantly, it retains the
2′-amino functionality (see Fig. 5). Substitution of 2AP at G5
abrograted cleavage of the true PPT/U3 junction, resulting
instead in a miscleavage in U3 two nucleotides 3′ of the PPT/U3
junction (Fig. 6, lane 4). This implies that a guanine at position 5
is critical for proper PPT cleavage specificity and supports the
idea that the 2′-amino group is not critical. Overall, these
results, taken together with our previous in vivo data (Julias et
al., 2004; McWilliams et al., 2006), argue that the role of theposition 5 guanosine is primarily in helping to determine the
appropriate structure of the nucleic acid substrate necessary to
mediate RNase H cleavage of the PPT/U3, rather than in
making base-specific contacts with RT.
Mutations in the RNase H primer grip cause miscleavages at
the PPT/U3 junction, generating viral DNAs with aberrant
ends
Interactions between the RNase H domain of HIV-1 RT and
the nucleic acid substrate play an important role in RNase H
cleavage specificity at the PPT/U3 junction. We previously
compared the effects of mutations in the RNase H primer grip of
HIV-1 RT on the cleavage specificity of RNase H in vivo (Julias
et al., 2002) and in vitro (Rausch et al., 2002). In general, there
was a reasonably good agreement between the two systems (in
vivo and in vitro) in terms of their effect on RNase H cleavage
specificity. However, the mutants that showed the most
significant loss of cleavage specificity both in vivo and in
vitro, namely Y501A and N474A/Q475A, appeared to behave
differently in the two assays. The N474A/Q475A double mutant
caused a loss of two nucleotides at the 2-LTR junction in vivo,
while the in vitro cleavage that would cause this two-nucleotide
deletion was not observed. Similarly, the Y501A mutation
caused an increase in 2- to 5-bp deletions in U3 of 2-LTR circle
junctions in vivo, however the corresponding miscleavages did
not predominate in the in vitro assay (Rausch et al., 2002).
In an effort to reconcile this apparent discrepancy in the
RNase H cleavage specificity in these two systems, we repeated
the in vitro experiments. In vitro assays were performed
comparing cleavages by the wild-type HIV-1 RT and the
Y501A, N474A, Q475A and N474A/Q475A mutant RTs. In
agreement with the previous analyses, both the Y501A mutant
and the N474A/Q474A double mutant were found to have the
Fig. 8. RNase H miscleavages cause small insertions and deletions in U3. The
sequence of the PPT nucleic acid substrate is shown. The PPT region is indicated
in green, U3 is indicated in red. Correct cleavage at the PPT/U3 junction
generates the appropriate U3 end that is the substrate for integration into the host
genome. However, the PPT double mutants U2/U5 and A2/A5 caused RNase H
miscleavages that would lead to 1 and 2-bp insertions in U3, respectively (see
Figs. 3 and 4). The Y501A HIV-1 RT mutant miscleaved to generate a 2-bp
deletion in U3, as indicated in Fig. 7.
Fig. 7. Mutations in the RNase H primer grip of HIV-1 RT cause significant alterations in PPT cleavage specificity in vitro. (A) RNase H cleavage profile of the wild-
type and mutant PPTs by wild-type (WT) and mutant HIV-1 RTs (Y501A, Q475A, N474A, and Q475A/N474A). Reactions were performed as described (see
Materials and methods). The full-length 5′-end-labeled RNA and site of PPT/U3 cleavage are indicated by arrows to the right and left of the gel.
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no cleavages were observed at the true PPT/U3 junction, the
main cleavage site for both mutants was in U3, two nucleotides
3′ of the PPT/U3 junction. This result explains the two-
nucleotide deletions seen in the U3 region of 2-LTR circle
junctions obtained from cells infected with these mutant viruses
(Julias et al., 2002) (see Fig. 8). Individually, the N474A and
Q475A mutants were found to have a modest effect on the
specificity of RNase H cleavage in vitro [Fig. 7, lanes 11–20
(see also Rausch et al., 2002)]. These in vitro results are in
better agreement with the in vivo results and strengthen the
argument that most of the miscleavages caused by G-tract
mutations occur when the PPT is being generated, not when it is
removed.
Does mispairing in the G-tract contribute to RNase H cleavage
specificity at the PPT/U3 junction?
As mentioned previously, analysis of the crystal structure of
HIV-1 RT bound to an RNA/DNA duplex containing the PPT
showed that there are two unpaired and two mispaired bases
within the PPT (Sarafianos et al., 2001). However, the available
biochemical data have suggested these when this nucleic acid is
free in solution, these same base pairs are not mispaired, but are
base paired relatively weakly (Kvaratskhelia et al., 2002). These
observations imply that it is the binding to HIV-1 RT that
disrupts the base pairing in the PPT. It should be noted,
however, that in the crystal structure of the RT-PPT complex,
the mispaired PPT/U3 junction is not aligned with the RNase Hactive site. This raises the question of whether the putative
mispaired segment would still be mispaired when the PPT is
aligned for proper cleavage at the junction. Put another way,
would the mispaired segment remain at the same position
relative to the RNase H active site irrespective of the alignment
of HIV-1 RT and the PPT (i.e., does the mispaired region have
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when the PPT/U3 junction is aligned for cleavage?).
In an attempt to address these questions, we introduced a
series of nucleotide substitutions in the G-tract region of the
RNA (primer) and DNA (template) strands in our in vitro
cleavage assay so as to disrupt the predicted base pairing.
Assuming that the mispaired region in these RNA/DNA
duplexes remained a constant distance from the RNase H
active site, the predicted alignment would be as shown in Fig.
9A. If the G-tract of the PPT adopted a similar structure as the
mispaired portion of the A-tract, one would expect that both G3
(RNA primer) and C5 (DNA template) would be unpaired; and
G4 and G5 (RNA primer) would shift to base pair with C3 and
C4 (DNA template), respectively. In one set of experiments we
found that disruption of the G5:C5 base pair in the PPT reduced
the specificity of RNase H cleavage at the PPT/U3 junction
(Fig. 9B), but that cleavage specificity could be restored when
compensatory mutations were introduced in the normal pairing
positions on the opposing stand. In particular, a change of C5 to
T in the DNA template strand completely abolished cleavage at
the PPT/U3 junction (Fig. 9B, lane 3), although the PPT/U3
cleavage was partially restored when the complementary A5
mutation was introduced into the opposing RNA primer strand
(Fig. 3, lane 3). Similarly, the A4/A5 double substitution in the
RNA strand also reduced cleavage at the PPT/U3 junction; an
effect that was restored by the compensatory C5 to T5 mutation
in the opposing DNA strand (T5, Fig. 9B, compare lanes 14 and
16). In another set of experiments we found that mutation of C6
to T6 in the DNA template did not disrupt processing at theFig. 9. Base pairing interactions in the G-tract influences RNase H cleavage specifi
mispairing observed in A-tract. The data suggest that the G-tract does not conform
designed to analyze possible base mispairing in the G-tract. Mutations were introduce
mutants represent mutations introduced in the RNA strand. T4, G4, T5, T6, and
preformed as described (see Materials and methods). The full-length 5′-end labeled
center of the gels.PPT/U3 junction (Fig. 9B, lane 4), and that either G3 to A3 or
G4 to A4 changes did not significantly alter cleavage specificity
at the junction (Fig. 9B, lanes 6 and 10). Taken together, these
results suggest that the integrity of the base pair at position 5 is
important for PPT recognition and cleavage specificity at the
PPT/U3 junction, whereas base pair interactions at adjacent
positions 3, 4 and 6 are not.
Discussion
The molecular mechanism(s) that control the precise
cleavage of the PPT/U3 junction by RNase H are not well
understood. The analysis of the 2-LTR circle junctions makes it
possible to determine the effects of mutations in RT and the PPT
on the cleavage specificity of RNase H in vivo. Although this
technique is valuable, it permits only the monitoring of the final
DNA product and cannot usually be used to determine which
cleavage step is affected the mutations. In particular, when
insertions are seen at the 2-LTR circle junctions it is unclear
whether these insertions are due to a failure to correctly
generate, or completely remove, the PPT primer.
To address these questions, we analyzed the ability of wild-
type and HIV-1 RT mutants to cleave normal, mutant, and
modified PPTs in vitro. These results, obtained in vitro, are
entirely consistent with the previously reported in vivo data
(Julias et al., 2002; Julias et al., 2004; McWilliams et al., 2006),
and support the conclusion that both positions 2 and 5 in the G-
tract of the PPT play important roles in cleavage specificity at
the PPT/U3 junction. In vivo, most single mutations in the G-city at the PPT/U3 junction. (A) Model for mispairing in the G-tract based on
to this mispaired alignment. (B) RNase H cleavage profile of G-tract mutants
d in either the DNA or RNA strand, or both, as indicated. The A3, A4 and A4/A5
T4/T5 represent mutations made in the DNA strand. Cleavage reactions were
RNA and site of PPT/U3 cleavage are indicated by arrows to the left, right and
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mutations at positions 2 and 5 increased the proportion of 2-
LTR circle junctions containing insertions. The results of our in
vitro analyses of these same mutations suggest that the 1–2
nucleotide insertions at the 2-LTR circle junctions are caused by
failure to generate the correct PPT primer, rather than by a
failure to completely remove the PPT primer. While both
positions 2 and 5 appeared to be important for PPT processing,
the guanosine at position 5 was found to have a particularly
important role in determining the specificity of PPT cleavage in
both the in vitro and in vivo experiments. We found that
substitution of either inosine (removing the 2-amino group) or
2-aminopurine (removing the C6 carboxyl oxygen) at G5
greatly reduced the efficiency of cleavage at the PPT/U3
junction while no significant miscleavages were seen when an
inosine substitution was introduced at position G2 in the PPT.
Furthermore, our in vitro results also show that the integrity of
the G5:C5 base pair is critical for appropriate RNase H
processing at the PPT/U3 junction; disruption of this base pair
significantly altered PPT cleavage specificity.
Molecular modeling analyses predicted that there was a
potentially important base specific contact between the 2′-
amino group of G5 and the carboxyl oxygen of Q475 in the
RNase H primer grip of HIV-1 RT (Sarafianos et al., 2001). This
interpretation was supported by our data showing that
elimination of the 2-amino group from guanosine (by
substituting inosine at position 5) resulted in reduced RNase
H cleavage specificity. However, additional in vitro experiments
with a PPT with 2AP at position 5 lead us to propose that the
primary role of G5 is in the structure of the PPT and not in
specific contacts with the RT. This conclusion is supported by
in vivo experiments monitoring the 2-LTR circle junctions
generated by viral vectors that had mutations in positions 2 and
5 of the PPT, combined with mutations at positions 475 or 501
of RT (McWilliams et al., 2006).
One of the striking features of the crystal structure of HIV-1
RT bound to an RNA/DNA duplex containing the PPT is the
mispairing in the PPT (Sarafianos et al., 2001). Because the PPT
in this structure is not aligned with the RNase H active site in a
way that would allow cleavage at the PPT/U3 junction, it is not
known whether there is mispairing when the PPT is properly
aligned for cleavage. It is possible that the mispairing of bases,
caused by the binding of RT to the nucleic acid, and which
portion of the PPT is mispaired, is determined primarily by
contacts with RT. In theory, this could cause mispairing in a
different sequence, such as the G-tract (see Fig. 9), when the
PPT was aligned with RT for cleavage at the PPT/U3 junction.
Previous biochemical analysis showed that the A-rich sequence
near the 5′-end of the PPT, which is mispaired in the crystal
structure of the HIV-1 RT/PPT complex, is weakly paired or
unpaired in solution (Kvaratskhelia et al., 2002). This suggests
that it would be particularly easy for HIV-1 RT binding to
disrupt the normal base pairing in this region and that this
sequence would be mispaired irrespective of the alignment of
the PPT substrate and the RNase H active site.
Our in vitro approach to this question was to ask whether
proper cleavage at the PPT/U3 junction depended on strictbase pairing at all positions in the G-tract in the PPT.
Although proper cleavage does not require base pairing at all
positions in the G-tract, the data do not support the model
presented in Fig. 9. There does appear to be a significant
requirement for base pairing at position 5. One would expect
that the G-tract at the 3′-end of the PPT would be strongly
base-paired, making it relatively difficult for HIV-1 RT
binding to disrupt the base pair at position 5 in the G-tract.
This idea is supported by our results, which show that one of
the base pairs in the G-tract appears to be essential for proper
cleavage at the PPT/U3 junction. The available data instead
support a model in which accurate cleavage at the PPT/U3
junction depends in part on the ability of the A-tract to be
mispaired in a complex with HIV-1 RT, which would help to
prevent inappropriate cleavage within the PPT. The mispairing
would make this portion of the RNA/DNA duplex flexible
which would also help to position the RNase H active site at
the PPT/U3 junction. The inability of the G-tract to undergo a
similar mispairing would account for the conservation of G-
tract at the 3′-end of the PPT.
Many retroviral PPTs share a similar overall organization: an
A-tract near the 5-end of the PPT, often ending with an AGA
sequence, and a G-tract near the 3-end of the PPT. Specific
differences in the PPT sequences of different retroviruses could
be selected by the specific structure of the cognate RT and its
interactions with a particular PPT, although this does not appear
to involve base specific interactions. Overall, the ability of a
particular RNase H to properly recognize, bind to, and
appropriately cleave its cognate PPT appears determined by
the capacity of the PPT bound to the appropriate RT to assume a
structure that leads to the proper alignment of the RNase H
active site for cleavage at the PPT/U3 junction. In this sense,
because the sequence of the PPT determines its structure,
appropriate RNA cleavage is sequence-dependent.
Materials and methods
Materials
Wild-type and mutant HIV-1 RT was expressed and purified
by metal chelate chromatography as previously described
(Boyer et al., 2001). DNA oligonucleotides were purchased
from Biosource International. RNA oligonucleotides were
purchased from Dharmacon.
RNA labeling
RNA oligonucleotides containing the HIV-1 PPT sequence
were 5′-end labeled using T4 polynucleotide kinase (T4
PNK) and [γ32P]ATP at 37 °C for 1 h. The reaction was
stopped by the addition of 2 volumes of formamide loading
buffer (FLB). Products were purified by denaturing gel
electrophoresis, visualized by autoradiography and eluted in
10 mM Tris–HCl (pH 8.0), 0.1 mM EDTA, 250 mM NaCl
and 2% SDS overnight at 4 °C. The RNA was then ethanol
precipitated and resuspended in 10 mM Tris–HCl, 1 mM
EDTA (pH 8.0).
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The RNase H cleavage assay was performed at 37 °C in
50 mM Tris–HCl (pH 8.0), 50 mM NaCl, 8 mM MgCl2, and
5 mM DTT. PPT hybrid substrates were prepared by annealing
the 5′-end-labeled RNA oligonucleotides to their complemen-
tary DNA oligonucleotides at 90 °C for 5 min and slow cooled
to room temperature in 10 mM Tris–HCl (pH 8.0), 1 mM
EDTA, and 50 mM NaCl. The PPT substrate was then briefly
incubated in cleavage buffer at 37 °C for 1 min prior to the
addition of wild-type or mutant HIV-1 RT (42 ng). Cleavage
reactions were performed at 37 °C for a period of 5 min unless
otherwise noted. The reaction was quenched by the addition of
2 volumes of formamide loading buffer (FLB). Cleavage
products were resolved by 12% denaturing gel electrophoresis
and visualized by autoradiography.
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